EHACART
The research shows an emerging target for the development of novel CAR T-cell immunotherapies.
The researchers reported “high rates of durable responses” in most patients who were in high-risk disease subgroups.
Idecabtagene vicleucel led to “deeper and more durable responses” than standard regimens in the KarMMa-3 trial.
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.